

NOVADEL PHARMA INC  
Form 8-K  
December 01, 2009

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT  
TO SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): November 24, 2009

NOVADEL PHARMA INC.  
(Exact Name of Registrant as Specified in Its Charter)

Delaware  
(State or other jurisdiction  
of incorporation or  
organization)

001-32177  
(Commission File No.)

22-2407152  
(I.R.S. Employer  
Identification No.)

25 Minneakoning Road  
Flemington, New Jersey 08822  
(Address of principal executive offices) (Zip Code)

(908) 782-3431  
(Registrant's telephone number, including area code)

N/A  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On November 24, 2009, the Compensation Committee of the Board of Directors of NovaDel Pharma Inc. (the "Company") approved the proposal to grant 700,000 stock options, in accordance with the Company's 1998 Stock Option Plan, to Dr. David H. Bergstrom. These options are exercisable in equal monthly installments over a period of twenty-four months and have an exercise price of \$0.23 per share (equal to the fair market value on the date of grant, which is the last closing price on November 23, 2009) and will expire on November 24, 2014.

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NovaDel Pharma  
Inc.

By: /s/ Steven B.  
Ratoff

Name: Steven B. Ratoff

Title: Chairman, Interim  
Chief Financial  
Officer, Interim  
President and  
Chief Executive  
Officer

Date: December 1, 2009

---

